Apple Stock Slides 7% as Weak Sales Forecast Overshadows Quarterly Earnings Beat 
Amazon Q2 Earnings Beat Estimates as AWS AI Growth Surges, But Q3 Revenue Forecast Disappoints 
OpenAI Revenue Surges After GPT-5.6 Launch as IPO Expectations Grow 
Sony Raises Full-Year Outlook After Q1 Profit Jumps 40% on Gaming and Chip Growth 
Meta-backed research finds exposure to ‘untrustworthy’ social media is rare. The fine print is less reassuring 
Sony Eyes $1.3 Billion Tamron Acquisition as Lens Maker Reviews Offer 
Qualcomm Stock Falls as Weak Q4 Forecast, Apple Revenue Decline Overshadow AI Data Center Growth 
Chipotle Q2 Earnings Beat Expectations as Sales Growth Drives Higher 2026 Outlook 
Japan Earthquake Disrupts Auto and Chip Supply Chains 
Meta Stock Drops After Earnings Miss as AI Spending and Legal Costs Weigh on Profit 
Robinhood Q2 Earnings Beat Estimates, But HOOD Stock Falls as Investors Question Profit Quality 
Roblox Stock Drops 16% as Q3 Bookings Forecast Misses Expectations 
Holcim Raises 2026 Outlook After Strong Q2 Earnings Beat 
Warner Bros. Discovery Shares Rise as Newsom Pushes Settlement in $110 Billion Merger Fight 
Microsoft Stock Jumps as Azure Growth, AI Revenue Beat Expectations 
Apple Q3 Earnings Beat as Record iPhone Sales Offset Services, China Weakness 
Toyota First-Half Global Sales and Production Decline on Weak China Demand, RAV4 Transition 
CHESTERBROOK, Pa., April 26, 2018 -- Trevena, Inc. (NASDAQ:TRVN) today announced that it will host a conference call and webcast on Thursday, May 3, 2018 at 8:00 am EDT to review financial results for the quarter ended March 31, 2018 and to discuss recent corporate highlights.
To join the call, please dial-in at (855) 465-0180 (conference ID: 1350009).
To join a live audio webcast of the call, please visit the Investor Presentation section of the Company’s website (conference ID: 1350009). Following the conclusion of the call, the webcast will be available for replay for 30 days.
About Trevena
Trevena, Inc. is a biopharmaceutical company focused on providing better, safer therapies to patients in pain. The Company has leveraged breakthrough science to discover and develop its investigational product, oliceridine injection, for the management of moderate-to-severe acute pain. Oliceridine has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration, and is intended to provide healthcare providers an innovative new option for patients who require an intravenous opioid. The Company also has an early stage pipeline of new chemical entities targeting novel mechanisms of action, including TRV250 for acute migraine, neuropathic pain, and other indications.
Contacts
Trevena, Inc.
Investors:
Jonathan Violin, Ph.D.
Senior Vice President, Scientific Affairs & Investor Relations Officer
610-354-8840 x231
[email protected]
or
Media:
Public Relations
[email protected]
